Kymera dou­bles down on pro­tein de­graders for im­munol­o­gy, chas­ing Dupix­ent and So­tyk­tu

Look­ing to fur­ther ex­pand the reach of pro­tein de­graders be­yond can­cer, Kymera Ther­a­peu­tics re­vealed two new pro­grams Thurs­day morn­ing that it hopes will com­pete with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER